State-of-the-art approaches to sentinel node biopsy for breast cancer:
Identifieur interne : 005636 ( Istex/Corpus ); précédent : 005635; suivant : 005637State-of-the-art approaches to sentinel node biopsy for breast cancer:
Auteurs : Hiram S. Cody Iii ; Patrick I. BorgenSource :
- Surgical Oncology [ 0960-7404 ] ; 2000.
Abstract
Sentinel lymph node (SLN) biopsy has the potential to become a standard operation for most patients with operable breast cancer, but raises a number of issues for the surgeon and institution wishing to start a SLN program. We began to perform SLN biopsy for breast cancer at Memorial Sloan-Kettering Cancer Center in September of 1996. Based on a pilot study of 60 patients, detailed analyses of our first 500 and 1000 cases, and a cumulative experience of 1500 procedures, we report the lessons learned in starting a SLN program, emphasizing study design, case selection, technique and quality control. All patients had clinical T1-2N0 breast cancers and isotope plus blue dye mapping. The combination of blue dye and isotope localization was superior to either method alone, unfiltered technetium sulfur colloid was superior to filtered, and optimum isotope localization was achieved with a low-volume, low-dose intradermal injection. In our first 1000 cases, 14% of SLN were found by isotope alone, and 8% by dye alone. 10% of positive SLN were found by isotope alone, and 11% by dye alone. Failed and false-negative SLN procedures were less frequent as experience increased.
Url:
DOI: 10.1016/S0960-7404(99)00029-8
Links to Exploration step
ISTEX:B7BCA5E2DEE3C77B5A449CD6149E47CA88568800Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title>State-of-the-art approaches to sentinel node biopsy for breast cancer:</title><author><name sortKey="Cody Iii, Hiram S" sort="Cody Iii, Hiram S" uniqKey="Cody Iii H" first="Hiram S" last="Cody Iii">Hiram S. Cody Iii</name><affiliation><mods:affiliation>The Breast Service, Department of Surgery, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York 10021, USA</mods:affiliation></affiliation><affiliation><mods:affiliation>E-mail: codyh@mskcc.org</mods:affiliation></affiliation></author><author><name sortKey="Borgen, Patrick I" sort="Borgen, Patrick I" uniqKey="Borgen P" first="Patrick I" last="Borgen">Patrick I. Borgen</name><affiliation><mods:affiliation>The Breast Service, Department of Surgery, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York 10021, USA</mods:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:B7BCA5E2DEE3C77B5A449CD6149E47CA88568800</idno><date when="2000" year="2000">2000</date><idno type="doi">10.1016/S0960-7404(99)00029-8</idno><idno type="url">https://api.istex.fr/document/B7BCA5E2DEE3C77B5A449CD6149E47CA88568800/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">005636</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">005636</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a">State-of-the-art approaches to sentinel node biopsy for breast cancer:</title><author><name sortKey="Cody Iii, Hiram S" sort="Cody Iii, Hiram S" uniqKey="Cody Iii H" first="Hiram S" last="Cody Iii">Hiram S. Cody Iii</name><affiliation><mods:affiliation>The Breast Service, Department of Surgery, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York 10021, USA</mods:affiliation></affiliation><affiliation><mods:affiliation>E-mail: codyh@mskcc.org</mods:affiliation></affiliation></author><author><name sortKey="Borgen, Patrick I" sort="Borgen, Patrick I" uniqKey="Borgen P" first="Patrick I" last="Borgen">Patrick I. Borgen</name><affiliation><mods:affiliation>The Breast Service, Department of Surgery, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York 10021, USA</mods:affiliation></affiliation></author></analytic><monogr></monogr><series><title level="j">Surgical Oncology</title><title level="j" type="abbrev">SO</title><idno type="ISSN">0960-7404</idno><imprint><publisher>ELSEVIER</publisher><date type="published" when="2000">2000</date><biblScope unit="volume">8</biblScope><biblScope unit="issue">2</biblScope><biblScope unit="page" from="85">85</biblScope><biblScope unit="page" to="91">91</biblScope></imprint><idno type="ISSN">0960-7404</idno></series></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0960-7404</idno></seriesStmt></fileDesc><profileDesc><textClass></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Sentinel lymph node (SLN) biopsy has the potential to become a standard operation for most patients with operable breast cancer, but raises a number of issues for the surgeon and institution wishing to start a SLN program. We began to perform SLN biopsy for breast cancer at Memorial Sloan-Kettering Cancer Center in September of 1996. Based on a pilot study of 60 patients, detailed analyses of our first 500 and 1000 cases, and a cumulative experience of 1500 procedures, we report the lessons learned in starting a SLN program, emphasizing study design, case selection, technique and quality control. All patients had clinical T1-2N0 breast cancers and isotope plus blue dye mapping. The combination of blue dye and isotope localization was superior to either method alone, unfiltered technetium sulfur colloid was superior to filtered, and optimum isotope localization was achieved with a low-volume, low-dose intradermal injection. In our first 1000 cases, 14% of SLN were found by isotope alone, and 8% by dye alone. 10% of positive SLN were found by isotope alone, and 11% by dye alone. Failed and false-negative SLN procedures were less frequent as experience increased.</div></front></TEI><istex><corpusName>elsevier</corpusName><keywords><teeft><json:string>axillary</json:string><json:string>isotope</json:string><json:string>node</json:string><json:string>breast cancer</json:string><json:string>axilla</json:string><json:string>surg</json:string><json:string>biopsy</json:string><json:string>lymphatic</json:string><json:string>intradermal</json:string><json:string>borgen</json:string><json:string>axillary dissection</json:string><json:string>giuliano</json:string><json:string>breast cancer patients</json:string><json:string>oncol</json:string><json:string>sentinel</json:string><json:string>krag</json:string><json:string>melanoma</json:string><json:string>oncology</json:string><json:string>sentinel node biopsy</json:string><json:string>lymphatics</json:string><json:string>surg oncol</json:string><json:string>injection site</json:string><json:string>cody</json:string><json:string>localization</json:string><json:string>memorial cancer center</json:string><json:string>dissection</json:string><json:string>isotope injection</json:string><json:string>backup axillary dissection</json:string><json:string>sentinel lymph node biopsy</json:string><json:string>intradermal injection</json:string><json:string>study design</json:string><json:string>sentinel lymphadenectomy</json:string><json:string>quality control</json:string><json:string>biopsy cavity</json:string><json:string>lymphatic mapping</json:string><json:string>conventional axillary dissection</json:string><json:string>gamma probe</json:string><json:string>systemic adjuvant therapy</json:string><json:string>coll surg</json:string><json:string>serial sections</json:string><json:string>patient selection</json:string><json:string>tumor site</json:string><json:string>sentinel lymph node</json:string><json:string>isotope localization</json:string><json:string>biopsy procedures</json:string><json:string>sentinel node</json:string><json:string>pilot study</json:string><json:string>breast</json:string><json:string>lymph</json:string><json:string>injection</json:string></teeft></keywords><author><json:item><name>Hiram S Cody, III</name><affiliations><json:string>The Breast Service, Department of Surgery, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York 10021, USA</json:string><json:string>E-mail: codyh@mskcc.org</json:string></affiliations></json:item><json:item><name>Patrick I Borgen</name><affiliations><json:string>The Breast Service, Department of Surgery, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York 10021, USA</json:string></affiliations></json:item></author><language><json:string>eng</json:string></language><originalGenre><json:string>Full-length article</json:string></originalGenre><abstract>Sentinel lymph node (SLN) biopsy has the potential to become a standard operation for most patients with operable breast cancer, but raises a number of issues for the surgeon and institution wishing to start a SLN program. We began to perform SLN biopsy for breast cancer at Memorial Sloan-Kettering Cancer Center in September of 1996. Based on a pilot study of 60 patients, detailed analyses of our first 500 and 1000 cases, and a cumulative experience of 1500 procedures, we report the lessons learned in starting a SLN program, emphasizing study design, case selection, technique and quality control. All patients had clinical T1-2N0 breast cancers and isotope plus blue dye mapping. The combination of blue dye and isotope localization was superior to either method alone, unfiltered technetium sulfur colloid was superior to filtered, and optimum isotope localization was achieved with a low-volume, low-dose intradermal injection. In our first 1000 cases, 14% of SLN were found by isotope alone, and 8% by dye alone. 10% of positive SLN were found by isotope alone, and 11% by dye alone. Failed and false-negative SLN procedures were less frequent as experience increased.</abstract><qualityIndicators><score>6.905</score><pdfVersion>1.2</pdfVersion><pdfPageSize>570 x 795 pts</pdfPageSize><refBibsNative>true</refBibsNative><keywordCount>0</keywordCount><abstractCharCount>1178</abstractCharCount><pdfWordCount>4649</pdfWordCount><pdfCharCount>28067</pdfCharCount><pdfPageCount>7</pdfPageCount><abstractWordCount>188</abstractWordCount></qualityIndicators><title>State-of-the-art approaches to sentinel node biopsy for breast cancer:</title><pii><json:string>S0960-7404(99)00029-8</json:string></pii><genre><json:string>research-article</json:string></genre><host><title>Surgical Oncology</title><language><json:string>unknown</json:string></language><publicationDate>1999</publicationDate><issn><json:string>0960-7404</json:string></issn><pii><json:string>S0960-7404(00)X0008-4</json:string></pii><volume>8</volume><issue>2</issue><pages><first>85</first><last>91</last></pages><genre><json:string>journal</json:string></genre></host><categories><wos><json:string>science</json:string><json:string>surgery</json:string><json:string>oncology</json:string></wos><scienceMetrix><json:string>health sciences</json:string><json:string>clinical medicine</json:string><json:string>oncology & carcinogenesis</json:string></scienceMetrix><inist><json:string>sciences appliquees, technologies et medecines</json:string><json:string>sciences biologiques et medicales</json:string><json:string>sciences medicales</json:string></inist></categories><publicationDate>2000</publicationDate><copyrightDate>2000</copyrightDate><doi><json:string>10.1016/S0960-7404(99)00029-8</json:string></doi><id>B7BCA5E2DEE3C77B5A449CD6149E47CA88568800</id><score>1</score><fulltext><json:item><extension>pdf</extension><original>true</original><mimetype>application/pdf</mimetype><uri>https://api.istex.fr/document/B7BCA5E2DEE3C77B5A449CD6149E47CA88568800/fulltext/pdf</uri></json:item><json:item><extension>zip</extension><original>false</original><mimetype>application/zip</mimetype><uri>https://api.istex.fr/document/B7BCA5E2DEE3C77B5A449CD6149E47CA88568800/fulltext/zip</uri></json:item><istex:fulltextTEI uri="https://api.istex.fr/document/B7BCA5E2DEE3C77B5A449CD6149E47CA88568800/fulltext/tei"><teiHeader><fileDesc><titleStmt><title level="a">State-of-the-art approaches to sentinel node biopsy for breast cancer:</title><title level="a" type="sub">Study design, patient selection, technique, and quality control at Memorial Sloan-Kettering Cancer Center</title></titleStmt><publicationStmt><authority>ISTEX</authority><publisher>ELSEVIER</publisher><availability><p>©2000 Elsevier Science Ltd</p></availability><date>2000</date></publicationStmt><notesStmt><note type="content">Table 1: Reported experience with SLN biopsy for breast cancer (20 series)</note><note type="content">Table 2: Relative success of isotope and blue dye in finding the SLN in 1000 patients at MSKCCa</note><note type="content">Table 3: Relative success of isotope and blue dye in finding the positive SLN in 253 patients at MSKCCa</note><note type="content">Table 4: Successful SLN localization by method of biopsya</note><note type="content">Table 5: Comparison of unfiltered and filtered Tc-99m sulfur colloid</note><note type="content">Table 6: Comparison of intradermal and intraparenchymal injection of isotopea</note></notesStmt><sourceDesc><biblStruct type="inbook"><analytic><title level="a">State-of-the-art approaches to sentinel node biopsy for breast cancer:</title><title level="a" type="sub">Study design, patient selection, technique, and quality control at Memorial Sloan-Kettering Cancer Center</title><author xml:id="author-0000"><persName><forename type="first">Hiram S</forename><surname>Cody, III</surname></persName><email>codyh@mskcc.org</email><note type="correspondence"><p>Corresponding author. Tel.: 212-639-8261; fax: 212-794-5812</p></note><affiliation>The Breast Service, Department of Surgery, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York 10021, USA</affiliation></author><author xml:id="author-0001"><persName><forename type="first">Patrick I</forename><surname>Borgen</surname></persName><affiliation>The Breast Service, Department of Surgery, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York 10021, USA</affiliation></author><idno type="istex">B7BCA5E2DEE3C77B5A449CD6149E47CA88568800</idno><idno type="DOI">10.1016/S0960-7404(99)00029-8</idno><idno type="PII">S0960-7404(99)00029-8</idno></analytic><monogr><title level="j">Surgical Oncology</title><title level="j" type="abbrev">SO</title><idno type="pISSN">0960-7404</idno><idno type="PII">S0960-7404(00)X0008-4</idno><imprint><publisher>ELSEVIER</publisher><date type="published" when="2000"></date><biblScope unit="volume">8</biblScope><biblScope unit="issue">2</biblScope><biblScope unit="page" from="85">85</biblScope><biblScope unit="page" to="91">91</biblScope></imprint></monogr></biblStruct></sourceDesc></fileDesc><profileDesc><creation><date>2000</date></creation><langUsage><language ident="en">en</language></langUsage><abstract xml:lang="en"><p>Sentinel lymph node (SLN) biopsy has the potential to become a standard operation for most patients with operable breast cancer, but raises a number of issues for the surgeon and institution wishing to start a SLN program. We began to perform SLN biopsy for breast cancer at Memorial Sloan-Kettering Cancer Center in September of 1996. Based on a pilot study of 60 patients, detailed analyses of our first 500 and 1000 cases, and a cumulative experience of 1500 procedures, we report the lessons learned in starting a SLN program, emphasizing study design, case selection, technique and quality control. All patients had clinical T1-2N0 breast cancers and isotope plus blue dye mapping. The combination of blue dye and isotope localization was superior to either method alone, unfiltered technetium sulfur colloid was superior to filtered, and optimum isotope localization was achieved with a low-volume, low-dose intradermal injection. In our first 1000 cases, 14% of SLN were found by isotope alone, and 8% by dye alone. 10% of positive SLN were found by isotope alone, and 11% by dye alone. Failed and false-negative SLN procedures were less frequent as experience increased.</p></abstract></profileDesc><revisionDesc><change when="2000">Published</change></revisionDesc></teiHeader></istex:fulltextTEI><json:item><extension>txt</extension><original>false</original><mimetype>text/plain</mimetype><uri>https://api.istex.fr/document/B7BCA5E2DEE3C77B5A449CD6149E47CA88568800/fulltext/txt</uri></json:item></fulltext><metadata><istex:metadataXml wicri:clean="Elsevier, elements deleted: ce:floats; body; tail"><istex:xmlDeclaration>version="1.0" encoding="utf-8"</istex:xmlDeclaration><istex:docType PUBLIC="-//ES//DTD journal article DTD version 4.5.2//EN//XML" URI="art452.dtd" name="istex:docType"></istex:docType><istex:document><converted-article version="4.5.2" docsubtype="fla"><item-info><jid>SO</jid><aid>83</aid><ce:pii>S0960-7404(99)00029-8</ce:pii><ce:doi>10.1016/S0960-7404(99)00029-8</ce:doi><ce:copyright type="full-transfer" year="2000">Elsevier Science Ltd</ce:copyright></item-info><head><ce:title>State-of-the-art approaches to sentinel node biopsy for breast cancer:</ce:title><ce:subtitle>Study design, patient selection, technique, and quality control at Memorial Sloan-Kettering Cancer Center</ce:subtitle><ce:author-group><ce:author><ce:given-name>Hiram S</ce:given-name><ce:surname>Cody</ce:surname><ce:suffix>III</ce:suffix><ce:cross-ref refid="AUT2"></ce:cross-ref><ce:cross-ref refid="CORR1">*</ce:cross-ref><ce:e-address>codyh@mskcc.org</ce:e-address></ce:author><ce:author><ce:given-name>Patrick I</ce:given-name><ce:surname>Borgen</ce:surname><ce:cross-ref refid="AUT3"></ce:cross-ref></ce:author><ce:affiliation><ce:textfn>The Breast Service, Department of Surgery, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York 10021, USA</ce:textfn></ce:affiliation><ce:correspondence id="CORR1"><ce:label>*</ce:label><ce:text>Corresponding author. Tel.: 212-639-8261; fax: 212-794-5812</ce:text></ce:correspondence></ce:author-group><ce:abstract><ce:section-title>Abstract</ce:section-title><ce:abstract-sec><ce:simple-para>Sentinel lymph node (SLN) biopsy has the potential to become a standard operation for most patients with operable breast cancer, but raises a number of issues for the surgeon and institution wishing to start a SLN program. We began to perform SLN biopsy for breast cancer at Memorial Sloan-Kettering Cancer Center in September of 1996. Based on a pilot study of 60 patients, detailed analyses of our first 500 and 1000 cases, and a cumulative experience of 1500 procedures, we report the lessons learned in starting a SLN program, emphasizing study design, case selection, technique and quality control. All patients had clinical T1-2N0 breast cancers and isotope plus blue dye mapping. The combination of blue dye and isotope localization was superior to either method alone, unfiltered technetium sulfur colloid was superior to filtered, and optimum isotope localization was achieved with a low-volume, low-dose intradermal injection. In our first 1000 cases, 14% of SLN were found by isotope alone, and 8% by dye alone. 10% of <ce:italic>positive</ce:italic> SLN were found by isotope alone, and 11% by dye alone. Failed and false-negative SLN procedures were less frequent as experience increased.</ce:simple-para></ce:abstract-sec></ce:abstract></head></converted-article></istex:document></istex:metadataXml><mods version="3.6"><titleInfo><title>State-of-the-art approaches to sentinel node biopsy for breast cancer:</title><subTitle>Study design, patient selection, technique, and quality control at Memorial Sloan-Kettering Cancer Center</subTitle></titleInfo><titleInfo type="alternative" contentType="CDATA"><title>State-of-the-art approaches to sentinel node biopsy for breast cancer:</title><subTitle>Study design, patient selection, technique, and quality control at Memorial Sloan-Kettering Cancer Center</subTitle></titleInfo><name type="personal"><namePart type="given">Hiram S</namePart><namePart type="family">Cody, III</namePart><affiliation>The Breast Service, Department of Surgery, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York 10021, USA</affiliation><affiliation>E-mail: codyh@mskcc.org</affiliation><description>Corresponding author. Tel.: 212-639-8261; fax: 212-794-5812</description><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Patrick I</namePart><namePart type="family">Borgen</namePart><affiliation>The Breast Service, Department of Surgery, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York 10021, USA</affiliation><role><roleTerm type="text">author</roleTerm></role></name><typeOfResource>text</typeOfResource><genre type="research-article" displayLabel="Full-length article"></genre><originInfo><publisher>ELSEVIER</publisher><dateIssued encoding="w3cdtf">2000</dateIssued><copyrightDate encoding="w3cdtf">2000</copyrightDate></originInfo><language><languageTerm type="code" authority="iso639-2b">eng</languageTerm><languageTerm type="code" authority="rfc3066">en</languageTerm></language><physicalDescription><internetMediaType>text/html</internetMediaType></physicalDescription><abstract lang="en">Sentinel lymph node (SLN) biopsy has the potential to become a standard operation for most patients with operable breast cancer, but raises a number of issues for the surgeon and institution wishing to start a SLN program. We began to perform SLN biopsy for breast cancer at Memorial Sloan-Kettering Cancer Center in September of 1996. Based on a pilot study of 60 patients, detailed analyses of our first 500 and 1000 cases, and a cumulative experience of 1500 procedures, we report the lessons learned in starting a SLN program, emphasizing study design, case selection, technique and quality control. All patients had clinical T1-2N0 breast cancers and isotope plus blue dye mapping. The combination of blue dye and isotope localization was superior to either method alone, unfiltered technetium sulfur colloid was superior to filtered, and optimum isotope localization was achieved with a low-volume, low-dose intradermal injection. In our first 1000 cases, 14% of SLN were found by isotope alone, and 8% by dye alone. 10% of positive SLN were found by isotope alone, and 11% by dye alone. Failed and false-negative SLN procedures were less frequent as experience increased.</abstract><note type="content">Table 1: Reported experience with SLN biopsy for breast cancer (20 series)</note><note type="content">Table 2: Relative success of isotope and blue dye in finding the SLN in 1000 patients at MSKCCa</note><note type="content">Table 3: Relative success of isotope and blue dye in finding the positive SLN in 253 patients at MSKCCa</note><note type="content">Table 4: Successful SLN localization by method of biopsya</note><note type="content">Table 5: Comparison of unfiltered and filtered Tc-99m sulfur colloid</note><note type="content">Table 6: Comparison of intradermal and intraparenchymal injection of isotopea</note><relatedItem type="host"><titleInfo><title>Surgical Oncology</title></titleInfo><titleInfo type="abbreviated"><title>SO</title></titleInfo><genre type="journal">journal</genre><originInfo><dateIssued encoding="w3cdtf">199908</dateIssued></originInfo><identifier type="ISSN">0960-7404</identifier><identifier type="PII">S0960-7404(00)X0008-4</identifier><part><date>199908</date><detail type="volume"><number>8</number><caption>vol.</caption></detail><detail type="issue"><number>2</number><caption>no.</caption></detail><extent unit="issue pages"><start>55</start><end>132</end></extent><extent unit="pages"><start>85</start><end>91</end></extent></part></relatedItem><identifier type="istex">B7BCA5E2DEE3C77B5A449CD6149E47CA88568800</identifier><identifier type="DOI">10.1016/S0960-7404(99)00029-8</identifier><identifier type="PII">S0960-7404(99)00029-8</identifier><accessCondition type="use and reproduction" contentType="copyright">©2000 Elsevier Science Ltd</accessCondition><recordInfo><recordContentSource>ELSEVIER</recordContentSource><recordOrigin>Elsevier Science Ltd, ©2000</recordOrigin></recordInfo></mods></metadata><serie></serie></istex></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/LymphedemaV1/Data/Istex/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 005636 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Istex/Corpus/biblio.hfd -nk 005636 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= LymphedemaV1
|flux= Istex
|étape= Corpus
|type= RBID
|clé= ISTEX:B7BCA5E2DEE3C77B5A449CD6149E47CA88568800
|texte= State-of-the-art approaches to sentinel node biopsy for breast cancer:
}}
| This area was generated with Dilib version V0.6.31. |  |